###### Strengths and limitations of this study

-   This is the first study to present detailed quantifiable differences in cancer research funding between male and female primary investigators in the UK.

-   Our study is dependent on the accuracy of original investment data from the funding bodies.

-   We could not openly access data of private sector research funding, nor were we able to obtain disaggregated data from Cancer Research UK.

-   While the gender discrepancies in cancer research funding observed in our study period are likely multifactorial, this study does not allow us to postulate any potential underlying mechanisms responsible for these observations.

Introduction {#s1}
============

Within the European Union (EU), women represent nearly half of the workforce and more than half of all university graduates; however, they are under-represented in senior positions in the workplace.[@R1] In science, research and development, the attrition rate among women exceeds that of their male counterparts at every stage of career progression in a phenomenon termed the 'leaky pipeline', with women representing 46% of PhD graduates, 33% of career scientists and 22% of grade A researchers (the highest posts at which research is conducted---equivalent to professorships in the UK).[@R2] In the field of medical science, women represent 17.8% of grade A researchers.[@R2] This problem is not limited to the EU, and several studies have similarly explored the gender imbalance in the USA.[@R3] Indeed data collected by Unesco suggest that just one in five countries worldwide has achieved gender parity in scientific research (defined as when 45% to 55% of researchers are women).[@R6] Previous studies have proposed a number of factors that may contribute towards this observed 'leaky pipeline' including societally defined traditional gender roles, attitudes towards career deviation and career breaks, lack of mentorship, institutional discrimination and sexual harassment.[@R7]

This problem is an ongoing concern both to policy-makers and to the science community at large, particularly within the science, technology, engineering, maths and medicine (STEMM) fields.[@R8] A number of initiatives have sought to highlight and promote change in order to address this issue. Gender equality is a central component of Horizon 2020, a flagship initiative to secure Europe's global competitiveness.[@R9] Whereas previous campaigns[@R10] have had unclear impact and in some instances been described as offensive to gender equality,[@R12] this will be one of the first efforts to be legally enshrine gender equality into research and innovation.[@R9] Three central objectives of Horizon 2020 include fostering gender balance in research teams, ensuring gender balance in decision-making panels and groups as well as integrating gender analysis in research and innovation content.

With regard to science research funding, men receive a 4.4% higher funding application success rate compared with women in the EU (31.8% success rate for men, 27.4% success rate for women).[@R13] Previous research has shown that in general, it is harder for women to obtain high prestige awards and that female applicants have proportionately more success when applying for smaller grants.[@R14]

In the biomedical sciences, women receive smaller grants compared with their male counterparts both in the USA[@R15] and the UK.[@R16] Women are noticeably under-represented in UK clinical oncology research[@R17] and gender discrepancies exist in the success rates of grant applications to UK funders.[@R18] Subconscious bias has been demonstrated in the decision-making of academic science recruiters[@R19] and also reported by those who assess grant applications.[@R18] Although gender discrepancies do appear to vary across specific fields of research, it has been previously reported that women do not appear overtly disadvantaged in social science research.[@R20]

Our group has previously undertaken a systematic comparison of infectious disease research funding by gender within the UK, showing clear and consistent differences between the genders in total funding and median award size, across a range of diseases and types of science.[@R21] Here we examine the distribution of cancer research funding awarded to men and women primary investigators (PIs) across specific cancers, funder categories and along the research and development (R&D) continuum.

Materials and methods {#s2}
=====================

Our methods build on those developed for previous analyses of infectious disease research investments, which are described in detail elsewhere,[@R22] and adapted in subsequent peer-reviewed publications ([www.researchinvestments.org/publications](www.researchinvestments.org/publications)).

We systematically examined funding awards from a number of public and philanthropic cancer research funding bodies (including the Medical Research Council, Department of Health, Biotechnology and Biological Sciences Research Council, Engineering and Physical Science Research Council, Wellcome Trust, European Commission, as well as nine members of the Association of Medical Research Charities) between 2000 and 2013. Information was obtained by downloading openly accessible information on the funder website, contacting the funder to request information or searching existing funding databases. For each award, the title and abstract, where available, were individually screened for relevance to cancer research. We excluded awards that were (1) not obviously or immediately relevant to oncology; (2) led by a non-UK institution; (3) not considered to be for R&D activity. Studies that were completed without funding were also excluded. Private sector data were not available to evaluate at the same level of detail as public and philanthropic research award data and were therefore excluded from this analysis. Cancer Research UK (CRUK) would not provide their funding data at individual award level and so could not be included in the main analysis.

We assigned each study to one of 16 primary cancer site categories and also as many of 14 cross-cutting categories as appropriate. To reduce the impact of skew due to small sample size, we restricted our cancer site analysis to those site-specific cancers with at least 15 studies across both sexes. As a result, testicular (14 studies), bone (13 studies), bladder (10 studies), thyroid (4 studies) and cholangiocarcinoma (2 studies) were excluded from our site-specific cancer analysis.

The 14 cross-cutting categories were paediatric, geriatric, infection-associated, women's health, men's health, occupational health, pathogenesis, diagnostic/screening/monitoring, drug therapy, radiotherapy, surgery, immunology, psychosocial and global health. The 'other\' category was only used when none of the aforementioned categories were deemed to be appropriate. We allocated studies to one of five categories along the R&D continuum: preclinical; phase I, II or III clinical trials; product development (including phase IV activity); public health; and cross-disciplinary research. Cross-disciplinary awards were defined as studies that clearly considered research across two or more different types of science (eg, preclinical science leading into a phase I trial).

Where the PI was named as the recipient of an award, the PIs were categorised as male or female. Where there was any uncertainty as to gender there was further scrutiny via review of the literature, institutional websites or publicly available publications and documents. Where we were finally unable to identify a PI's gender, the study was assigned as 'unclear'. Where the recipient PI of an award was not identified, the study was assigned as 'unspecified'.

Where awards were described in currencies other than UK pounds, these were converted to UK pounds using the mean exchange rate in the year of the award. All included awards were adjusted for inflation and reported in 2013 UK pounds.

We report descriptive statistics including median, IQR and percentages for categorical variables. Data were graphically inspected for normality using histograms. Mann-Whitney U tests were performed to test for univariate associations between gender and funding. Data were collated in Microsoft Excel 2010 and statistical analysis was performed using R studio (V.0.99.903) and Stata (V.13).

Results {#s3}
=======

In our analysis of cancer research investment awarded by public and philanthropic funding bodies to UK institutions between 2000 and 2014, we identified 4299 funded studies suitable for inclusion. These studies represented a sum total monetary investment of almost £2.4 billion. Of these, 53 studies (1.2%, total investment of £33.2 million) did not specify PI name or gender, while we were unable to ascertain the gender of the named PI for a further 60 studies (1.4%, total investment of £21.8 million). Therefore, 4186 awards, totalling £2.33 billion, were included in our final gender analysis ([table 1](#T1){ref-type="table"}, [figures 1 and 2](#F1 F2){ref-type="fig"}).

![Proportion of annual UK cancer research funding by gender.](bmjopen-2017-018625f01){#F1}
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###### 

Gender-specific UK cancer research funding by cancer site, disease theme, phase of research and development pipeline and by funding organisation

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                            Male PIs   Female PIs      Fold difference                                                                                                     
  ----------------------------------------- ---------- --------------- ----------------- ------------------------ ------ ------------- ------------- ------------------------ ------ ----- -----------
  All                                       2890       1 821 637 149   630 324\          252 647\                 1296   511 570 050   394 730\      198 485\                 3.6    1.6   1.3\*\*\*
                                                                       (1 662 559)       (127 343--553 560)                            (666 574)     (99 317--382 650)                     

  Cancer site                                                                                                                                                                              

   Head and neck                            16         17 490 769      1 093 173\        637 418\                 4      759 863       189 965\      183 250\                 23.0   5.8   3.5
                                                                       (1 046 928)       (260 926--2 242 703)                          (148 630)     (61 937--317 994)                     

   Cervical                                 15         12 678 187      845 212\          353 754\                 10     1 281 813     128 181\      123 623\                 9.9    6.6   2.9\*\*
                                                                       (1 070 241)       (94 896--1 574 367)                           (96 538)      (30 732--206 392)                     

   Prostate                                 71         125 769 548     1 771 402\        377 700\                 18     9 090 234     505 013\      188 950\                 13.8   3.5   2.0
                                                                       (6 980 741)       (190 072--893 840)                            (740 863)     (103 103--360 595)                    

   Colorectal                               93         57 301 015      616 139\          287 749\                 46     18 296 468    397 749\      176 320\                 3.1    1.6   1.6
                                                                       (750 261)         (112 437--893 840)                            (522 529)     (73 736--404 692)                     

   Breast                                   325        82 761 091      254 649\          166 321\                 235    52 971 924    225 412\      122 721\                 1.6    1.1   1.4
                                                                       (420 671)         (53 832--212 298)                             (414 352)     (22 583--220 325)                     

   Upper gastrointestinal and oesophageal   23         12 946 692      562 900\          274 268\                 13     8 736 139     672 011\      190 546\                 1.5    0.8   1.4
                                                                       (650 867)         (103 500--9 18 058)                           (1 659 329)   (75 424--240 704)                     

   Lung                                     42         17 589 619      418 800\          159 766\                 35     5 712 151     163 204\      127 698\                 3.1    2.6   1.3
                                                                       (740 402)         (88 544--284 718)                             (192 192)     (57 173--174 667)                     

   Ovarian                                  21         36 259 818      1 812 991\        266 344\                 25     7 974 217     318 968\      224 595\                 4.5    5.7   1.2
                                                                       (5 165 397)       (147 327--1 214 534)                          (372 325)     (119 951--276 184)                    

   Brain                                    9          3 223 573       358 174\          406 122\                 12     6 667 742     555 645\      346 106\                 0.5    0.6   1.2
                                                                       (170479)          (215 197--503 831)                            (651 240)     (162 573--702 297)                    

   Haematological                           791        263 742 072     333 428\          191 200\                 360    112 494 439   312 484\      180 981\                 2.3    1.1   1.1
                                                                       (446 336)         (122 138--279 643)                            (530 741)     (112 896--250 059)                    

   Skin                                     44         14 797 603      336 309\          89 456\                  42     7 305 773     173 947\      85 375\                  2.0    1.9   1.0
                                                                       (562 447)         (70 635--345 581)                             (292 287)     (68 113--215 519)                     

   Renal                                    11         7 727 390       702 490\          296 803\                 8      6 158 106     769 763\      542 768\                 1.3    0.9   0.6
                                                                       (675 521)         (90 509--1 270 928)                           (727 809)     (347 399--822 950)                    

   Mesothelioma                             17         2 267 977       133 410\          104 084\                 10     2 013 884     201 388\      202 921\                 1.1    0.7   0.5\*\*
                                                                       (117 199)         (65 607--174 656)                             (49 059)      (165 605--248 573)                    

   Liver                                    24         11 279 988      469 999\          250 892\                 12     13 515 306    1 126 276\    598 732\                 0.8    0.4   0.4\*
                                                                       (516 869)         (138 579--687 402)                            (1 207 998)   (240 881--1 679 106)                  

   Pancreatic                               9          4 566 168       507 352\          260 473\                 5      3 685 298     737 059\      1 033 948\               1.2    0.7   0.3
                                                                       (568 171)         (150 980--650 203)                            (461 259)     (236 145--1 033 948)                  

  Disease theme                                                                                                                                                                            

   Psychosocial                             43         11 524 430      268 010\          164 422\                 66     9 057 598     137 236\      59 994\                  1.3    2.0   2.7\*\*
                                                                       (422 656)         (43 523--274 442)                             (251 616)     (20 803--209 699)                     

   Men's health                             84         133 173 641     1 585 400\        364 401\                 22     9 429 269     428 603\      174 513\                 14.1   3.7   2.1\*
                                                                       (6 430 067)       (186 031--855 034)                            (687 483)     (87 844--318 514)                     

   Surgery                                  54         33 398 798      618 496\          272 279\                 14     3 723 997     265 999\      131 481\                 9.0    2.3   2.1\*
                                                                       (722 494)         (109 099--977 969)                            (538 442)     (20 000--243 687)                     

   Diagnostic, screening and monitoring     454        277 375 628     610 959\          248 793\                 201    71 024 311    353 354\      155 330\                 3.9    1.7   1.6\*\*\*
                                                                       (1 353 526)       (109 256--638 341)                            (509 792)     (75 224--294 584)                     

   Radiotherapy                             89         82 782 734      930 143\          283 654\                 19     5 123 806     269 674\      202 125\                 16.2   3.5   1.4
                                                                       (2 689 204)       (130 224--445 594)                            (265 442)     (68 219--357 426)                     

   Drug therapy                             736        488 185 281     663 295\          221 228\                 336    111 111 295   330 688\      175 374\                 4.4    2.0   1.3\*\*\*
                                                                       (2 265 942)       (116 730--553 560)                            (510 148)     (79 949--253 435)                     

   Women's health                           361        129 487 265     358 690\          168 523\                 265    67 078 971    253 128\      131 248\                 1.9    1.4   1.3
                                                                       (1 320 959)       (64 649--222 843)                             (487 672)     (22 790--230 625)                     

   Immunology (inc biologics)               304        141 667 662     466 012\          244 741\                 143    50 385 497    352 346\      206 604\                 2.8    1.3   1.2
                                                                       (885 702)         (130 741--483 283)                            (383 905)     (117 699--437 074)                    

   Pathogenesis                             1714       999 693 849     583 252\          269 893\                 775    355 962 017   459 305\      225 586\                 2.8    1.3   1.2\*\*\*
                                                                       (1 032 142)       (141 355--538 430)                            (765 925)     (123 782--448 560)                    

   Paediatrics                              115        37 509 650      326 170\          179 839\                 57     23 804 132    417 616\      182 305\                 1.6    0.8   1.0
                                                                       (465 935)         (81 614--310 647)                             (693 945)     (113 785--318 681)                    

   Infection-associated                     87         36 098 390      414 924\          221 742\                 40     18 326 629    458 165\      244 555\                 2.0    0.9   0.9
                                                                       (821 771)         (131 430--436 959)                            (706 563)     (140 757--481 060)                    

   Global health                            7          5 003 769       714 824\          105 132\                 5      1 431 191     286 238\      154 344\                 3.5    2.5   0.7
                                                                       (1 421 938)       (58 229--540 990)                             (308 533)     (98 699--377 559)                     

   Geriatrics                               3          921 777         307 259\          100 259\                 4      694 617       173 654\      178 014\                 1.3    1.8   0.6
                                                                       (409 655)         (42 410--779 108)                             (88 857)      (99 022--248 286)                     

   Occupational health                      14         1 993 492       142 392\          123 659\                 3      549 492       183 164\      199 998\                 3.6    0.8   0.6
                                                                       (128 096)         (25 355--198 248)                             (34 345)      (143 649--205 845)                    

  Phase of research and development                                                                                                                                                        

   Phase I--III                             182        175 953 897     966 779\          217 248\                 109    38 598 339    354 113\      117 699\                 4.6    2.7   1.9\*\*\*
                                                                       (4 287 134)       (101 493--700 972)                            (608 791)     (66 500--236 145)                     

   Product development                      106        86 729 963      818 207\          230 722\                 54     14 765 649    273 437\      150 469\                 5.9    3.0   1.5\*\*
                                                                       (2 787 935)       (109 099--515 754)                            (407 013)     (39 528--251 035)                     

   Public health                            304        162 533 528     534 649\          236 768\                 181    68 169 795    376 628\      160 196\                 2.4    1.4   1.5\*\*\*
                                                                       (882 173)         (91 284--484 162)                             (886 999)     (59 973--273 731)                     

   Cross-disciplinary                       285        237 828 497     834 486\          274 442\                 146    74 822 967    512 486\      223 617\                 3.2    1.6   1.2\*\*
                                                                       (1 879 331)       (136 009--806 082)                            (791 038)     (105 842--448 477)                    

   Preclinical                              1996       1 154 505 166   578 409\          256 606\                 802    315 115 408   392 912\      214 876\                 3.7    1.5   1.2\*\*\*
                                                                       (1 131 681)       (140 073--528 959)                            (602 354)     (121 572--435 243)                    

  Funding organisation                                                                                                                                                                     

   Department of Health                     337        326 868 815     969 937\          273 251\                 209    71 189 261    340 618\      175 000\                 4.6    2.8   1.6\*\*\*
                                                                       (3 477 639)       (109 256--858 065)                            (513 879)     (75 424--281 131)                     

   MRC                                      505        640 884 752     1 269 079\        592 592\                 253    188 994 003   747 011\      434 495\                 3.4    1.7   1.4\*\*\*
                                                                       (2 052 363)       (351 917--1 348 289)                          (943 859)     (254 487--748 000)                    

   Wellcome                                 121        116 858 787     965 775\          250 809\                 70     23 266 670    332 381\      194 697\                 5.0    2.9   1.3\*
                                                                       (2 035 860)       (165 274--689 373)                            (609 652)     (154 344--266 487)                    

   Charity (excluding Wellcome and CRUK)    1101       281 584 160     255 753\          163 214\                 585    130 457 245   223 003\      137 865\                 2.2    1.1   1.2\*\*\*
                                                                       (372 649)         (90 000--230 289)                             (427 557)     (67 135--206 068)                     

   EPSRC                                    292        163 856 870     561 153\          319 486\                 63     37 693 709    598 312\      258 057\                 4.3    0.9   1.2
                                                                       (939 912)         (147 583--605 290)                            (1 126 384)   (114 605--600 998)                    

   BBSRC                                    416        186 189 724     447 571\          373 556\                 88     35 754 106    406 296\      385 328\                 5.2    1.1   1.0
                                                                       (410 166)         (268 819--509 467)                            (277 730)     (290 714--480 990)                    

   European Commission (inc ERC)            36         56 188 966      1 560 805\        1 414 393\               9      14 693 323    1 632 591\    1 383 393\               3.8    1.0   1.0
                                                                       (426 113)         (1 261 751--1 768 211)                        (395 550)     (1 361 130--2 063 706)                

   Other                                    82         49 205 075      600 061\          144 907\                 19     9 521 733     501 143\      50 403\                  5.2    1.2   2.9
                                                                       (2 096 627)       (92 673--268 658)                             (773 838)     (25 092--1 013 231)                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cancer sites with fewer than 15 total awards are not presented in this table.

We were unable to identify the phase of research and development for 26 studies.

\*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001.

BBSRC, Biotechnology and Biological Sciences Research Council; CRUK, Cancer Research UK; EPSRC, Engineering and Physical Science Research Council; ERC, European Research Council; MRC, Medical Research Council; PI, primary investigator.

There were 2890 grants (69%) with a total value of £1.82 billion (78%) awarded to male PIs, while female PIs received 1296 grants (31%) with a total value of £512 million (22%). The median grant value was greater for men (£252 647; IQR: £127 343--£553 560) than for women (£198 485; IQR: £99 317--£382 650). Men received statistically significant larger grants in terms of median value compared with women (P\<0.001). Similarly, mean grant value was greater for men (£630 324; SD £1 662 559) than for women (£394 730; SD: £666 574). Across all cancer research funding grants awarded, male PIs received 3.6 times the sum investment value, 1.6 times the mean award value and 1.3 times the median award values compared with their female counterparts.

There was a statistically significant difference between the genders in median grant value for research funding in three specific cancer sites. Men received 2.9 times the funding of women PIs in cervical cancer (P\<0.001). Women received 2.4 and 2.0 times the funding of men in liver cancer (P\<0.05) and mesothelioma (P\<0.01), respectively. The differences in median funding for all other cancer sites were not statistically significant.

Some of the greatest apparent gender discrepancies in cancer funding by site are observed in awards for sex-specific cancers. For prostate cancer, male PIs receive 13.8, 3.5 and 2.0 times the investment of their female counterparts in total, mean and median funding, respectively. In cervical cancer research, men receive 9.9, 6.6 and 2.9 times the funding of women PIs in total, mean and median funding, respectively. In ovarian cancer research, there was a 4.6-fold, 5.7-fold and 1.2-fold difference between men and women in total, mean and median funding, respectively. And similarly in breast cancer, there was a 1.6-fold, 1.1-fold and 1.4-fold difference between men and women in total, mean and median funding, respectively.

Men received more total investment than women across all disease themes. A statistically significant difference in median grant value between the genders was present for 6 of the 14 disease themes included in our analysis. Men received greater median funding in all six of these disease themes: pathogenesis (1.2-fold difference, P\<0.001); drug therapy (1.3-fold difference, P\<0.001); diagnostic, screening and monitoring (1.6-fold difference, P\<0.001); psychosocial (2.7-fold difference, P\<0.01); men's health (2.1-fold difference, P\<0.05); and surgery (2.1-fold difference, P\<0.05).

In keeping with our findings in our site-specific analysis, there was a consistent trend of increased funding for male PIs in sex-specific cancer research. In men's health, there was a 14.1-fold, 3.7-fold and 2.7-fold difference in favour of male PIs in terms of total, mean and median investment, respectively. In women's health, there was a 1.9-fold, 1.4-fold and 1.3-fold difference in favour of male PIs in total, mean and median investment, respectively.

Male PIs receive statistically significant greater median funding than women at all points of the R&D pipeline: preclinical (1.2-fold difference, P\<0.001); phase I, II, or III clinical trials (1.9-fold difference, P\<0.001); product development research (1.5-fold difference, P\<0.01); cross-disciplinary research (1.2-fold difference, P\<0.01); and public health (1.5-fold difference, P\<0.001).

With the exception of the Biotechnology and Biological Sciences Research Council, all funding organisations on average awarded larger median awards to men than to women. These differences were statistically significant for four funding bodies: Medical Research Council (1.4-fold difference, P\<0.001), charities---excluding Wellcome Trust (1.2-fold difference, P\<0.001), Department of Health (1.6-fold difference, P\<0.001) and Wellcome Trust (1.3-fold difference, P\<0.05).

Discussion {#s4}
==========

In this first quantifiable systematic comparison of UK cancer research investment by PI gender for the period 2000--2013, we demonstrate that female PIs clearly and consistently receive less funding than their male counterparts in terms of total investment, the number of funded awards, mean funding awarded and median funding awarded. This apparent absolute and relative discrepancy in funding largely persisted regardless of analysis by cancer site, disease theme, research and development pipeline, or by funder.

Our study is a purely descriptive analysis which does not and cannot assess any potential explanatory mechanism that might underlie our observed gender discrepancy in cancer research funding. It cannot for example account for any potential influence of conscious or subconscious gender bias in cancer research funding decisions, and there is no evidence here of any bias on the part of funding bodies. We would caution against drawing conclusions regarding factors that may influence our reported observations from this study alone. Instead, we would advocate that these results be interpreted within the context of the existing scientific body of evidence on the topic. Nevertheless, this study provides further evidence into the apparent funding gap between the sexes in biomedical research.[@R15]

The attrition rate among women exceeds that of their male counterparts at every stage of scientific career progression.[@R2] Existing data show that women are under-represented at the highest research posts in the UK, accounting for 23.2% of professors as of 2010,[@R13] who would likely represent the great majority of PIs, particularly in larger awards. The lack of information on seniority and track record of funding applicants is an important gap in this study and precludes the conclusion that gender bias is responsible for the observed differences in cancer research funding. Indeed, if gender equality were to be achieved in medical science, a generational lag effect may be expected before this was reflected in funding data.

However, there is mounting evidence to suggest that the existing gender imbalances in researcher numbers do not wholly explain the observable gender gap in funding. At all stages of career progression, female scientists tend to experience lower success rates compared with male scientists when applying for research funding.[@R25] Even when success rates are equal, female scientists tend to receive less in terms of award value.[@R16] This is reflected by internal annual reports by Research Councils UK which represents a strategic partnership between seven of the UK research councils, awards from three of which have been included in our analysis. Female researchers made up 24% of standard grant applications (shorter in duration than 4 years or less than £1 million in value) and experienced a success rate of 25% compared with 29% among male applicants.[@R29] This gender difference is even more pronounced for large grants (both longer than 4 years in duration and greater than £1 million in value) where women make up 17% of applicants and their success rate is 24% compared with 38% among their male counterparts.[@R29]

Within the UK, the Equality Challenge Unit set up the Athena SWAN charter in 2005. This scheme aims to tackle gender inequalities in STEMM by awarding bronze, silver or gold awards to universities, research institutions or departments which can demonstrate their commitment to reducing inequalities with measurable performance data. In 2011, the National Institute for Health Research (NIHR) decided that they would only consider application from research groups with at least a Silver Athena SWAN award,[@R30] thereby further incentivising engagement with this scheme. Recent evidence suggests that there has been an associated positive impact in the advancement of gender equality as reported by participants of the scheme.[@R31] Furthermore, in the latest call for research professorships, the NIHR guidance has specified a maximum of two nominations per institution at least one of which must be female.[@R32]

Further to those discussed, there are several additional limitations to our study. We are dependent on the accuracy of the original investment data sourced from the funding bodies. Private sector data was excluded from this study due to incompleteness of publicly available data from this sector. We were not able to include data on applicant success rate, the amount of funding initially requested, the gender co-applicants for each grant, the total gender pool of researchers in each disease area and within each type of science, or the proportion of awards made to clinical and non-clinical researchers, all of which would have provided a more holistic understanding of the research landscape. We lacked data on the academic rankings of PIs and were unable to adjust for seniority across both genders. Unfortunately, CRUK would not provide disaggregated funding data and so could not be included in our full analysis. However, the proportion of CRUK studies awarded by PI gender was comparable to our reported results (online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}).

10.1136/bmjopen-2017-018625.supp1

While the gender discrepancies in cancer research funding observed over the 13-year study period are likely multifactorial, this study is fundamentally descriptive in nature and does not allow us to postulate the underlying mechanisms responsible for the observed gender differences. Nevertheless, this study demonstrates substantial gender imbalances in cancer research investment. We would strongly urge policy-makers, funders and the academic and scientific community to investigate the factors leading to our observed differences and seek to ensure that women are appropriately supported in scientific endeavour.
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